DSM-Firmenich AG (AMS: DSFIR)
Market Cap | 25.97B |
Revenue (ttm) | 12.46B |
Net Income (ttm) | -188.00M |
Shares Out | 265.28M |
EPS (ttm) | -0.71 |
PE Ratio | n/a |
Forward PE | 26.23 |
Dividend | 0.93 (0.95%) |
Ex-Dividend Date | n/a |
Volume | 850,590 |
Open | 97.92 |
Previous Close | 98.10 |
Day's Range | 97.10 - 98.86 |
52-Week Range | 85.86 - 124.85 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Feb 13, 2025 |
About DSM-Firmenich AG
DSM-Firmenich AG provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. It operates through Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and s... [Read more]
Financial Performance
In 2023, DSM-Firmenich AG's revenue was 10.63 billion, an increase of 26.66% compared to the previous year's 8.39 billion. Earnings were 2.13 billion, an increase of 25.80%.
Financial StatementsNews
DSM-Firmenich AG (KDSKF) Q3 2024 Earnings Call Transcript
Reducing Cattle’s Footprint
Cow flatulence is a significant contributor to the greenhouse gas in our atmosphere. Dutch company DSM-Firmenich’s Bovaer addresses that issue at source: The feed additive slows down the last step of ...
DSM-Firmenich: Making Progress, Still Far From Delivering On Its Full Potential
Pavel Bittner birla por una llanta un sprint de foto-finish a Van Aert
El joven checo de 21 aos, del Team DSM-Firmenich, logr su tercera victoria de etapa como profesional
FutureFuel names Koninklijke's Polet as new CEO
FutureFuel names Koninklijke's Polet as new CEO
DSM-Firmenich AG (KDSKF) Q2 2024 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q2 2024 Earnings Conference Call July 30, 2024 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Dimitri de Vreeze - Chief Executive Officer Ralf S...
DSM-Firmenich AG (KDSKF) Q1 2024 Earnings Call Transcript
DSM-Firmenich AG (OTC:KDSKF) Q1 2024 Earnings Conference Call May 2, 2024 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Ralf Schmeitz - Chief Financial Officer Conference C...
Royal DSM: Quality At A Price
Royal DSM has proven its resilience through the near-term macro challenges. Its upcoming merger with Firmenich also appears promising and could deliver upside going forward.
Koninklijke DSM N.V. (RDSMY) CEO Geraldine Matchett on Q2 2022 Results - Earnings Call Transcript
Koninklijke DSM N.V. (OTCQX:RDSMY) Q2 2022 Results Conference Call August 2, 2022 8:00 AM ET Company Participants Dave Huizing - Vice President of Investor Relations Geraldine Matchett - Chief Executi...
Health and biotech firm says it has enjoyed resilient demand as health kick is here to stay
Dimitri de Vreeze, co-CEO of DSM, discusses his company's earnings and explains why demand has remained strong.
'A merger of equals': Firmenich CEO Ghostine on DSM deal
Firmenich CEO Gilbert Ghostine describes the company's deal with sector peer DSM as a "merger of equals."
5 Great Green Stocks Making a Direct Impact
It's the end of business as usual. To save the planet, consumers, companies and governments all over the world are stepping up their sustainability game, or at least pledging to do so.
Koninklijke DSM N.V. (RDSMY) on Q4 and FY 2021 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) on Q4 and FY 2021 Results - Earnings Call Transcript
DSM co-CEO: Inflationary pressures offset by 4% price increase in some business areas
Geraldine Matchett, co-CEO of DSM and member of CNBC's ESG Council, provides a deep dive into the company's fourth-quarter results and shares how DSM are tackling rising inflation.
Very Confident to Increase Our Outlook: DSM Co-CEO
Aug.04 -- DSM Co-CEO Dimitri de Vreeze discusses the company's earnings, emissions and sustainable foods. He speaks with Bloomberg's Anna Edwards and Mark Cudmore on "Bloomberg: European Market Open".
Koninklijke DSM NV (RDSMY) CEO Dimitri de Vreeze on Q4 2020 Results - Earnings Call Transcript
Koninklijke DSM NV (RDSMY) CEO Dimitri de Vreeze on Q4 2020 Results - Earnings Call Transcript
DSM Going Into 2021 With Positive Momentum, Says Co-CEO
Feb.16 -- Geraldine Matchett, co-chief executive officer at at Dutch Lifesciences company Koninklijke DSM NV, discusses fourth-quarter earnings, the animal nutrition business and her outlook for the b...
Koninklijke DSM N.V. (RDSMY) Dimitri de Vreeze on Q3 2020 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) Dimitri de Vreeze on Q3 2020 Results - Earnings Call Transcript
'Analysts failed to see the impact of foreign exchange headwinds on top line,' DSM co-CEO says
Geraldine Matchett and Dimitri de Vreeze, co-CEOs at DSM, discuss the company's third-quarter earnings and the impact of the pandemic on the business.
Koninklijke DSM N.V. (RDSMY) Dimitri Vreeze on Q2 2020 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) Dimitri Vreeze on Q2 2020 Results - Earnings Call Transcript
DSM co-CEO's say cash generation 'is a big focus' amid the coronavirus crisis
Geraldine Matchett and Dimitri de Vreeze, co-CEO's of DSM, speak to the corporation's first half of the year along with its strategy amid the uncertainty of a second wave.
Koninklijke DSM NV (RDSMY) Q1 2020 Results - Earnings Call Transcript
Koninklijke DSM NV (RDSMY) Q1 2020 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) CEO Feike Sijbesma on Q4 2019 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) CEO Feike Sijbesma on Q4 2019 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) Management on Q3 2019 Results - Earnings Call Transcript
Koninklijke DSM N.V. (RDSMY) Management on Q3 2019 Results - Earnings Call Transcript